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Whilst common genetic variation in many non-coding genomic regulatory regions are known to 
impart risk of colorectal cancer (CRC), much of the heritability of CRC remains unexplained. To 
examine the role of recurrent coding sequence variation in CRC aetiology, we genotyped 12,638 
CRCs cases and 29,045 controls from six European populations. Single-variant analysis identified a 
coding variant (rs3184504) in SH2B3 (12q24) associated with CRC risk (OR = 1.08, P = 3.9 × 10−7), and 
novel damaging coding variants in 3 genes previously tagged by GWAS efforts; rs16888728 (8q24) 
in UTP23 (OR = 1.15, P = 1.4 × 10−7); rs6580742 and rs12303082 (12q13) in FAM186A (OR = 1.11, 
P = 1.2 × 10−7 and OR = 1.09, P = 7.4 × 10−8); rs1129406 (12q13) in ATF1 (OR = 1.11, P = 8.3 × 10−9), 
all reaching exome-wide significance levels. Gene based tests identified associations between CRC 
and PCDHGA genes (P < 2.90 × 10−6). We found an excess of rare, damaging variants in base-excision 
(P = 2.4 × 10−4) and DNA mismatch repair genes (P = 6.1 × 10−4) consistent with a recessive mode 
of inheritance. This study comprehensively explores the contribution of coding sequence variation 
to CRC risk, identifying associations with coding variation in 4 genes and PCDHG gene cluster and 
several candidate recessive alleles. However, these findings suggest that recurrent, low-frequency 
coding variants account for a minority of the unexplained heritability of CRC.
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Heritable factors are thought to contribute to around 35% of the variation in risk of developing colorec-
tal Cancer (CRC)1–3. High-penetrance mutations responsible for Mendelian disorders such as Lynch 
Syndrome, familial adenomatous polyposis and MUTYH associated polyposis have been shown to 
account for around 5% of all CRC. Genome-wide association studies (GWAS) have vindicated the 
notion that common genetic variants also contribute to CRC risk. Over 25 risk SNPs identified through 
GWAS4–15 are collectively responsible for only around 1% of CRC heritability3 and so much of the genetic 
contribution to CRC risk currently remains enigmatic. It has been proposed that low frequency variants 
in coding regions, may have substantial effects on risk and so may explain an appreciable proportion of 
the heritability of complex disease16. Conventional GWAS arrays have been sub-optimally configured to 
genotype such low frequency recurrent variation, whilst large-scale sequencing has been constrained by 
cost and data analysis bottlenecks.
Exome sequencing studies in multiple populations have enabled the assembly of catalogues of 
well-characterised single nucleotide variants within the coding sequence of genes. Genotyping arrays 
have been formatted into “exon” arrays specifically designed to interrogate recurrent genetic variation 
with putative impact on gene function. We set out to test the hypothesis that variation within gene cod-
ing sequences is associated with CRC risk, by making use of the recently introduced Illumina Exon array.
Results
Post QC exome-wide analysis was based on 8,100 CRC cases and 21,820 controls from the six 
case-control series (Supplementary Tables 1 and 2). We also made use of genotypes for ~10,000 SNPs 
(~54% variants are non-synonymous) that were included in our previously published GWASs8,10, thus 
increasing power and providing additional exome array variant data on 4538 cases and 7225 controls 
(Supplementary Methods, Supplementary Table 3). Prior to the meta-analysis, we assessed the adequacy 
of the case-control matching and possibility of differential genotyping of cases and controls in individ-
ual studies using Quantile-Quantile (Q-Q) plots of test statistics (Supplementary Figure 6). Using data 
from the above 9 case-control series, we derived for each SNP joint odds ratios (ORs) and confidence 
intervals (CIs) in a meta-analysis under a fixed-effects model and determined the associated P values. 
Overall 72,162 non-monomorphic post-QC variants observed in at least 2 studies contributed to the 
combined meta-analysis totalling 12,638 cases and 29,046 controls (Supplementary Table 1). Of these 
variants, 29,117 variants were rare (MAF < 1%) and 32,809 variants exhibited MAF < 5%. We found no 
appreciable inflation of test statistics for the meta-analysis as a whole, λ90%bottom = 0.98, thereby excluding 
significant differential genotyping or cryptic population substructure (See Q-Q plot in Supplementary 
Figure 7)8,10,13.
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Single variant analysis. 17 variants showed evidence for an association with CRC which exceeded 
Bonferroni-corrected exome-wide threshold of statistical significance (Table  1, Supplementary Table 4, 
Supplementary Figure 7), 4 of these 17 variants were non-synonymous missense variants: (rs3184504 
(p.Trp263Arg) in SH2B3 (12q24; OR = 1.08, P = 3.9 × 10−7, effect allele frequency (EAF) = 0.52); 
rs16888728 (p.Pro215Gln) in UTP23 (8q24; OR = 1.15, P = 1.4 × 10−7, EAF = 0.10); two variants in 
FAM186A (12q13) - rs6580742 (p.Met2193Ile, OR = 1.11, P = 1.2 × 10−7, EAF = 0.19) and rs12303082 
(p.Lys187Gln, OR = 1.09, P = 7.4 × 10−8, EAF = 0.36)). Another variant within 12q13 loci rs1129406 
(12q13; OR = 1.11 P = 8.3 × 10−9, EAF = 0.41) is located within a splice region of ATF1. The rs3184504 
association highlights a novel CRC risk locus (Table 1, Supplementary Figure 8). The p.Trp263Arg amino 
acid change resides in exon 3 of the SH2B adaptor protein and is predicted to be benign and tolerated 
by PolyPhen17 and SIFT18. Though predicted to be located within a transcription factor binding site 
(POLR2A) in lymphoblastoid, leukaemia and glioblastoma cell lines, it seems unlikely affect binding 
according to RegulomeDB (score 3a)19 or influence expression of SH2B3 in lymphoblastoid cell lines20,21 
and other tissues22,23. Conditional analysis showed that rs3184504 genotype was sufficient to explain all 
of the effect at the 12q24 risk locus (Supplementary Table 5).
The 4 other novel SNPs rs16888728, rs6580742, rs12303082 and rs1129406 map to the previously 
described 8q24.1112,24 and 12q13.12 loci10 (Table  1). rs16888728 is located within exon 3 of UTP23 
(8q23.3, 117783975, p.Pro215Gln) and is in moderate linkage disequilibrium (LD) with rs16892766 
(8q23.3, 117630683)24 (D’ = 0.63, r2 = 0.30). Mutual adjustment was unable to distinguish the effects of 
rs16888728 on CRC risk from the previously described GWAS association, suggesting rs16892766 to be 
a primary signal (rs16888728, ORcond = 0.99, Pcond = 0.83; rs16892766, ORcond = 1.27, Pcond = 5.3 × 10−10) 
(Supplementary Table 6).
Detailed analysis of the 12q13 locus encompassing coding variants in ATF1 and FAM186A showed 
that three new variants are within a region of fairly extensive linkage disequilibrium (LD) (r2 = 0.31–0.68, 
D’ = 0.92–1) and in moderate LD with rs11169552, a previously identified through GWAS10 CRC risk 
locus (r2 = 0.08 − 0.24, D’ = 0.95–0.99). Both rs6580742 and rs12303082 are missense variants located 
within the exon 1 (rs6580742, chr12:50727811, p.Met2193Ile) and exon 3 (rs12303082, chr12:50754563, 
p.Lys187Gln) of FAM186A. Strongest signal at the locus (rs1129406) is a synonymous coding variant in 
ATF1 located within the splice region of gene, though it is unclear if the normal splicing of the gene is 
affected by the variant. rs6580742 is located within DNaseI hypersensitivity cluster and in eQTL with 
DIP2B and KIAA1463 expression in lymphoblastoid cell lines19,25,26 and cis-eQTL with ATF1 expression 
in esophagus mucosa, subcutaneous adipose tissue, tibial artery22,23. It is likely to affect binding according 
to RegulomeDB (score 1f)19,27. Conditional analyses indicate that all the association signals, including 
previously identified rs1116955210 (OR = 1.08, P = 2.55 × 10−5, ORcond = 1.02, Pcond = 0.35,EAF = 0.73), 
are explained by rs1129406, the splice region variant in ATF1 (Supplementary Table 7).
The remaining 10 SNPs in non-coding regions had been identified through our previous GWAS 
studies of CRC10,11,13,28–30. We subsequently applied conditional analysis to interrogate all CRC risk loci 
highlighted by the current study but found no evidence of multiple signals at 1q41, 8q24.21, 15q13.3, 
18q21.1, 19q13.11, 20p12.3 and 20q13.33 (Supplementary Tables 8–14).
We further explored if rs1129406 (ATF1, 12q13), rs12303082 (FAM186A, 12q13), rs6580742 
(FAM186A, 12q13), rs16888728 (UTP23, 8q24) and rs3184504 (SH2B3, 12q24) genotypes affect the 
CRC risk differentially by sex, age at diagnosis, tumor site, stage and MSI status (Supplementary Table 
15). Intriguingly, we found that rs16888728 is significantly associated with gender in case-only analy-
sis (OR = 1.21, P = 5.6 × −4) with no effect on CRC risk in males in case-control analysis (OR = 1.28, 
P = 5 × 10−8 in women and OR = 1.06 and P = 0.14 in men).
Gene-based analysis. Following on from these single variant analyses we conducted a gene-based 
analysis for rare (MAF < 1%) and low-frequency (MAF < 5%) variants observed in at least two cohorts 
(Supplementary Figure 9, Table 2). Meta-analysis of SKAT-O results showed some evidence of inflation 
SNP rsID Gene
Annota-
tion CHR BP
Risk 
Allele
Reference 
Allele
EAF 
(cases/controls)
N 
studies N cases
N  
controls OR P value
P value  
Bonferroni 
adjusted
rs1129406 ATF1 coding- synon 12 51203371 A G 0.43/ 0.40 6 4730 12603 1.11 8.30 × 10
−9 7.44 × 10−04
rs12303082 FA-M186A missense 12 50754563 A C 037/0.35 9 10207 19886 1.09 7.40 × 10
−8 6.63 × 10−03
rs6580742 FA-M186A missense 12 50727811 A G 0.20/0.19 9 12539 29208 1.11 1.20 × 10
−7 0.01
rs16888728 UTP23 missense 8 117783975 A G 0.11/0.10 8 10621 26779 1.15 1.40 × 10−7 0.01
rs3184504 SH2B3 missense 12 111884608 G A 0.53/0.51 9 12530 29197 1.08 3.90 × 10−7 0.03
Table 1.  Results of meta-analysis for variants reaching exome-wide level of significance (4 × 10-7) under 
a fixed effects model. EAF – effect allele frequency.
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(λ = 1.45 in analysis for low –frequency variants). Among the genes showing evidence of association in 
low-frequency variants analysis were tandemly located genes from protocadherin gamma gene cluster 
(PCDHGA3, PCDHGA2, PCDHGA1, PCDHGA4, PCDHGB1, 5q31.3, P < 2.9 × 10−6 ). The details of the 
SNPs contributing to PCDHG associations are given in Supplementary Table 16. None of the genes 
reached significance in rare – variant analysis.
Gene-ontology (GO) enrichment analysis implicated homophilic cell adhesion genes in CRC devel-
opment (Supplementary Table 17).
Search for candidate high-penetrance CRC alleles. Next, we searched for rare high penetrance 
CRC variants by analysis of rare damaging variants present in more than 3 CRC cases, but absent from 
controls. In the analysis of dominant alleles, we observed truncating variants in NWD1, CD1A, ZNF594, 
DNAH9, ZNF418, ABTB1 and HIST1H3A and two missense variants in GCN1L1 (Supplementary Table 
18 ). We also assessed the contribution of rare recessive alleles present in >3 cases, but absent in controls 
(Supplementary Table 18). Notable among these homozygotes were stop codon (p.Tyr90*) in the base 
excision repair gene, NTHL1, as well as homozygous missense variants in the DNA mismatch-excision 
repair gene, PMS1 (p.Thr75Ile) (Supplementary Figure 10). Overall we saw an excess of rare homozy-
gous variants in base excision repair (16/8100 cases vs. 10/21820 controls, OR = 4.31; P = 2.4 × 10−4) 
and mismatch repair genes (11/8100 cases vs. 5/21820 controls, OR = 5.93, P = 6.1 × 10−4) in cases 
(Supplementary Table 19).
We also sought evidence of compound heterozygosity in cases and identified two damaging NOTCH2 
variants and three damaging variants in DNAJC17 (DnaJ (Hsp40) homolog, subfamily C, member 17) 
that were observed to be present in heterozygous state at least twice in 2 and more cases, but absent in 
controls (Supplementary Table 20). NOTCH2 is regulated by Wnt signalling and known to have lower 
expression in colorectal and ovarian cancer31.
Discussion
We have identified coding variation in 4 genes (SH2B3, UTP23, FAM186A, ATF1) and PCDHG gene 
cluster that contribute to the risk of developing CRC. Three of the 4 genes with new coding variants 
influencing CRC risk had been identified by previous GWAS SNPs10,12,24. Novel association between the 
coding variant (rs3184504) in the SH2B3 gene has been described during the process of preparation and 
SetID Gene N of variants # Description Chr band p.value
(A) low frequency (MAF < 5%) variants (n = 16,585)
 ENSG00000254245 PCDHGA3 89
protocadherin 
gamma subfamily 
A, 3
5 q31.3 7.29E-07
 ENSG00000081853 PCDHGA2 90
protocadherin 
gamma subfamily 
A, 2
5 q31.3 7.49E-07
 ENSG00000204956 PCDHGA1 91
protocadherin 
gamma subfamily 
A, 1
5 q31.3 7.86E-07
 ENSG00000254221 PCDHGB1 82
protocadherin 
gamma subfamily 
B, 1
5 q31.3 1.43E-06
 ENSG00000262576 PCDHGA4 79
protocadherin 
gamma subfamily 
A, 4
5 q31.3 2.91E-06
(B) High and Moderate low frequency (MAF < 5%) variants (n = 16,081) 
 ENSG00000254245 PCDHGA3 83
protocadherin 
gamma subfamily 
A, 3
5 q31.3 2.59E-06
 ENSG00000081853 PCDHGA2 84
protocadherin 
gamma subfamily 
A, 2
5 q31.3 2.79E-06
 ENSG00000204956 PCDHGA1 85
protocadherin 
gamma subfamily 
A, 1
5 q31.3 2.96E-06
Table 2.  Meta-analysis of gene-based (SKAT-O) tests. Top significant results for SKAT-O gene-based test 
for different subsets. We used Bonferroni correction to identify Exome-Wide level of significance for each 
of the subgroup separately. Only variants, which were observed in at least two independant studies, were 
included in the analysis. Genes with less than 2 variants per gene were exluded. Variants were defined High 
and Moderate accordind to classification adapted by SnpEff. # N of variants is based by the number of SNPs 
located within the genes and may vary by study, e.g. in case of monomorphic alleles.
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review of this manuscript in an independent meta-analysis32. Perhaps the most interesting finding of 
this well-powered study is the observation that very few recurrent coding sequence variants contribute 
to CRC risk, and certainly not with major effect size (OR > 2.5).
The association between CRC risk and the adaptor protein, SH2B3, is interesting, since rs3184504 
results in a predicted benign non-synonymous amino acid substitution (p.Trp263Arg) within the plek-
strin homology domain of SH2B3. SH2B3 is induced upon JAK-STAT3 phosphorylation and is expressed 
at high levels in haematopoietic cells, but only at low levels in the normal colon. The protein is a regulator 
of cytokine signals at the cell surface through tyrosine kinase signalling cascades and is thought to act as 
a negative regulator of such signals at the cell surface to impart an anti-proliferative effect. A consanguin-
eous family has been reported which segregates a germline frameshift mutation in the Plekstrin homol-
ogy domain of SH2B3. Homozygous individuals developed various autoimmune phenotypes and one 
sibling developed acute lymphoblastic leukaemia (ALL) as an infant33. Somatic SH2B3 mutations have 
also been identified in 3% of ALL, suggesting that SH2B3 loss plays a role in initiation and progression of 
human leukaemia through dysregulated cytokine signalling. Interrogation of TCGA and Broad Institute 
sequence data from colorectal adenocarcinomas34–36 did not identify an excess of somatic mutations 
in SH2B3 (0.69% of samples carry deleterious mutations or copy number variations), suggesting that 
SH2B3 mutations are not drivers in CRC progression33. Genetic variation at the SH2B3 gene locus has 
been associated with various autoimmune related disorders including hepatitis37, rheumatoid arthritis38, 
hypothyroidism39, type 1 diabetes40, vitiligo41, rheumatoid arthritis and coeliac syndrome42, suggesting 
that SH2B3 dysfunction may be involved in mediating disordered immune function and thereby play a 
role in cancer susceptibility. Interestingly, SH2B3 is over-expressed in ovarian tumour cells with evidence 
for a role in activating signal transduction43. SH2B3 expression status may have paradoxical effects in 
cancer, dependent on cellular context.
The variant in UTP23 (rs16888728) also exerts a modest effect on CRC risk. The UTP23 transcript 
is expressed at modest levels in many tissue types. It has sequence homology to a yeast protein involved 
in ribosomal RNA processing and ribosome biogenesis. As such, it may be involved in alternative splic-
ing, although very little is known about the functional role of the human protein. The coding variant 
(rs16888728) is located within exon 3 of UTP23 and results in a non-conserved amino acid substitu-
tion (p.Pro215Gln, GERP score = − 0.543). Conditional analysis was unable to distinguish the effects 
of rs16888728 on CRC risk from that of the previously described24 GWAS association (rs16892766). 
Interrogation of tumour sequence databases reveals no significant excess of mutations in CRC (< 1% 
prevalence)34–36. However, UTP23 is amplified in ~5% of CRC tumours35,36 with significant correlation 
between UTP1 mRNA expression and copy number variation.
The SNP rs1129406, a splice site variant in ATF1, appears to explain the association signal at the 
12q13 locus, including that of a previous signal identified by GWAS (rs11169552)10. ATF1 is a transcrip-
tion factor that, when phosphorylated, induces transcriptional transactivation of target genes. Fusion 
of ATF1 with the Ewing’s Sarcoma gene, or with FUS, results in continuous signaling and sarcomatous 
tumour formation. Common variation has not been associated with other cancers, however significant 
cis-eQTL with ATF1 was detected for this variant in esophagus mucosa, subcutaneous adipose tissue 
and tibial artery22,23. Whilst there are no excess of somatic mutations in CRC tissue in TCGA or Broad 
data, rs1129406 may be the causative variant that explains the previous GWAS signal. The relationship of 
FAM186A to CRC risk is somewhat opaque, as very little is known about this gene. FAM186A appears to 
be a protein coding gene, rather than a lncRNA. Hence we cannot exclude the possibility that the effect 
is mediated through regulatory effects.
The gene-based test, SKAT-O, highlighted several genes from protocadherin gamma (PCDHG) gene 
cluster on chromosome 5 exhibiting a composite excess of coding variants and thereby indicating the 
gene is associated with CRC risk. Somatic genomic missense and nonsense mutations in one of the iden-
tified genes are present in 11.8% of CRC cases and up to 31% of all skin cuteneous melanomas (according 
to The Cancer Genome Atlas data)35. PCDHG gene cluster encodes 22 genes divided into 3 subfamily 
(A,B and C) based on sequence similarities with multiple transcripts generated by alternative splicing44. 
PCDH expression is observed in colon and long range epigenetic silencing of PCDH cluster region 
has been described in Wilm’s tumours45, breast cancers46 and colorectal adenomas and carcinomas47. 
Hence, PCDH genes play role of tumour suppressor and silencing mutations might be expected to have 
tumour-promoting effects. Whilst PCDHG cluster genes are strong candidates based on the analysis pre-
sented in this study, further work is required to confirm the role of these genes in cancer predisposition.
The identification of damaging alleles acting as rare recessive traits in genes that participate in DNA 
repair, with known paradigms in CRC susceptibility, such as NTHL1 (p.Tyr90*) and PMS1 (p.Thr75Ile) 
clearly require further study as these represent strong candidate recessive alleles. Recently NTHL1 
loss-of-function germline mutation has been described in families with adenomatous polyposis and 
progression to CRC inherited in recessive mode48, thus suggesting that the observed association is real 
and our search for rare damaging alleles is a successful approach to identify candidate variants. The 
observed excess of rare damaging variants in base-excision and mismatch repair genes suggests that 
the clinical importance of moderately penetrant, disease-causing, variants in DNA repair genes may be 
underestimated. However, further studies will require even larger sample sizes, given the rarity of the 
alleles, unless sequencing can identify new alleles in addition to those catalogued here. Indeed, many of 
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the genes with damaging variants represent strong candidates for validation in exome and whole genome 
sequencing efforts.
Given the expectation that uncommon functional variation might be associated with CRC risk, with 
larger effect size than common variation, it is surprising that we have identified so few new coding 
sequence variants, and that all of these exert modest effect sizes (OR 1.08–1.15). In a linear-mixed model 
analysis (Supplementary Material), we estimated that the genetic variants identified though previous 
GWAS and significant in our meta-analysis explain approximately 1.5 ± 0.7% of the total phenotypic var-
iance on the liability scale, while the newly identified variants account for only 0.4% of the total variance.
The Infinium Human Exome BeadChip 12v1.0 or 12v1.1 (Illumina Inc.) array was configured to iden-
tify coding sequence variants most likely to have functional consequences. Despite of its attractiveness 
as a cheap alternative to exome sequencing, exome array has some limitations and is not able to offer 
complete whole exome coverage of all possible functional variants and indels. Importantly, exome array 
was designed based on exome sequencing of 12,000 samples and enriched for multiple outcomes such 
as cardiovascular disease, obesity, diabetes, autism and cancer49, which may not be representative of our 
cohorts. There were some differences in the genotyping quality between various versions of arrays used 
in the analyses and many variants did not pass stringent quality control criteria. Around 70,000 SNPs 
were non-monomorphic in European populations, present in at least two studies and passed our QC 
measures.
The focus on genetic variants with potential detrimental functional consequences should also enhance 
the a priori likelihood of pathogenicity. Though limited in detection of indels with only 136 present on 
the chip, the study was well powered to detect plausible effect sizes and allele frequencies (Supplementary 
Figure 11). Indeed, the study size had 80% power to detect an OR > 3 provided the MAF was >0.001 
and an OR odds >1.8 if the MAF was 0.005. Whilst larger studies and/or meta-analysis might identify 
further coding variants with functional effects, the paucity of findings of recurrent low frequency coding 
variation impacting on CRC risk is intriguing. Because the causative gene mutations have been char-
acterised for almost all dominant high penetrance CRC families, it seems unlikely that rare recurrent 
alleles in European populations have yet to be identified with large effects (OR > 5), apart from private 
mutations or recessive traits that are unlikely to be discovered through designed commercial arrays. 
Hence, population-specific custom exome arrays as well exome and genome sequencing of trios and 
families may be a way forward to identify recurrent rare genetic variation of moderate effect of risk and 
private mutations.
Materials and Methods
Study populations. The study was based on six independent case control series from European pop-
ulations including Scotland (3,616 cases and 10,312 controls), England (4,558 cases and 11,249 controls), 
Germany (284 cases and 1,100 controls), Holland (480 cases and 480 controls), Spain (300 cases and 
300 controls) and Portugal (200 cases and 200 controls). Details regarding these participating studies are 
described in the Supplementary Data (available online). All cases had histologically confirmed adenocar-
cinoma of the colon or rectum (codes 153 or 154 International Classification of Diseases (ICD), 9th revi-
sion or ICD10 C18, C19 or C20 codes). The study was undertaken at participating centres with written 
informed consent in accordance with respective Institutional Review Boards (IRB)/Ethics Committees.
To enhance our power we made use of previously published GWASs8,10 thus providing ~10.000 exome 
array variant data on 3,549 cases and 3,698 controls from UK1 and UK2 studies, 3,158 cases and 3,073 
controls from Scotland Phase1, Scotland Phase2 and Scotland Phase3, and 1,794 cases and 2,686 controls 
from the VQ58 study8,13 (Supplementary Methods, Supplementary Tables 2, 3). After quality control and 
exclusion of expected and unexpected duplicates between studies we ended up with exome array variant 
data on 3,033 cases and 3,690 controls from UK1 and UK2 studies, 556 cases and 2,997 controls from 
Scotland Phase1, Scotland Phase2 and Scotland Phase3, and 949 cases and 538 controls from the VQ58 
study8,13. Study details, details of genotyping, quality control procedures, sample and SNPs exclusion 
for these GWAS-focussed studies have been published previously8 (Supplementary Data, Supplementary 
Tables 2, 3).
Exome Array Genotyping and Quality Control. DNA was extracted from EDTA-venous blood 
samples using standard methodologies at each centre. Genotyping was performed using the Infinium 
Human Exome BeadChip 12v1.0 or 12v1.1 (Illumina Inc., San Diego, CA), with genotype calling 
using Illumina GenCall for HumanExome-12v1.0 and HumanExome-12v1.1 versions called separately. 
Generation Scotland controls and a subset of the cases from the SOCCS study were genotyped using 
OmniExpressExome BeadChip 8v1.1 or 8v1.250 (Illumina Inc., San Diego, CA). A summary of the array 
SNP content51,52 and the respective SNP inventory53 have been provided previously. Standard quality 
procedure were applied, with further details of sample and probe exclusion in Supplementary Material 
and Supplementary Table 2. We compared MAF and genotyping call genotyping call rates between dif-
ferent version of arrays used in the current study and excluded all variants that showed some evidence 
of differences (Supplementary Figures 1,3). Additionally, we compared allele frequency to the 1000G data 
and UK exome array consortium (Supplementary Figure 2). Following standard quality-assurance and 
quality control measures this collaborative initiative provided information on 12,638 CRCs cases and 
29,045 controls (Supplementary Table 1).
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Statistical analysis. We designed the study according to an estimate of the sample size required to 
detect plausible effect sizes (OR = 1.5–5.0) at various rare allele frequencies (> 0.001). Following com-
pletion of the study and all QC measures, we re-estimated statistical power for a given sample size using 
QUANTO version 1.2.454 for the main effect of genetic variant and the log-additive model of inher-
itance stipulating a P-value of 5.5 × 10−7, which corresponds to Bonferroni-corrected exome-wide level 
of significance.
The association between individual variants and risk of CRC was evaluated in initial data analysis 
using unconditional logistic regression under a log-additive model of inheritance for each study sepa-
rately. To examine whether associations at each identified locus were independent, we conducted condi-
tional analysis by controlling for allelic dosage for the most significantly associated SNP at the locus. We 
subsequently applied conditional analysis to interrogate following CRC risk loci highlighted by the cur-
rent study: 1q41 controlling for rs6687758, 8q23.3 controlling for rs16892766 and/or rs16888728, 8q24.21 
controlling for rs10505477, rs6983267 and/or rs7014346, 11q32.1 controlling for rs3802842, 12q13.12 
controlling for rs6580742, rs12303082 and rs1129406, 12q24.12 controlling for rs3184504, 14q22.2 con-
trolling for rs4444235, 15q13.3 controlling for rs4779584, 18q21.1 controlling for rs4939827, 19q13.11 
controlling for rs10411210, 20p12.3 controlling for rs961253 and 20q13.33 controlling for rs4925386.
Individual study effect estimates (Odds ratios (OR) and associated 95% confidence intervals (CIs)) 
derived from logistic regression were combined in a meta-analysis. We used a fixed effect inverse var-
iance weighting model for meta-analysis to maximize discovery power of the current study55. Only 
non-monomorphic variants observed in at least two studies were included in the meta-analysis. We 
tested for over-dispersion of P-values in the meta-analysis by generating quantile-quantile (QQ) plots 
and deriving an inflation factor (λ ). Cochran’s Q statistic was used to test for heterogeneity and the I2 
statistic to quantify the proportion of the total variation due to heterogeneity. I2 values ≥ 75% were con-
sidered to indicate excessive heterogeneity56 and variants displaying I2 values > 75% in were excluded 
from further analysis. Taking all the above measures into account, 72,162 SNPs remained in the analysis, 
equating to a Bonferroni-corrected exome-wide threshold of statistical significance of 5.55 × 10−7. This 
is conservative given the likely linkage disequilibrium between some variants. We further examined top 
variants and excluded those that showed obvious problems with clustering and differences in cluster-
ing between versions of genotyping platforms in our analysis. This included monomorphic rs1058065 
(exm2255298).
Association by sex, age, stage (invasive, non-invasive), MSI status and tumour site (rectal [ICD9:154], 
colonic [ICD9:153]) for the top new variants were further explored using ordered logistic regression in 
case-only analysis. All statistical tests were two-sided.
Gene based and pathway analysis. To explore the effects of more than one variant in the same 
gene on CRC risk, we used the small-sample-adjusted unified test, SKAT-O57 with default weight on rare 
variants. All variants observed in at least two studies contributed to the SKAT-O results. We performed 
analyses for rare (MAF > 1%) and low frequency variants (MAF below 5%) including all and only High 
and Moderate effects as annotated by SnpEff  58. Due to the different number of variants in each indi-
vidual study we performed SKAT-O test separately for each individual study and combined summary 
statistics from individual SKAT results in a meta-analysis using “MetaSKAT” package in R59 Similarly 
to single-variant analysis we tested for over-dispersion of P-values by generating QQ plots and deriving 
an inflation factor (λ ). To account for multiple testing in these gene-based tests, we set the significance 
threshold to be P < 2 × 10−6 to reflect Bonferroni correction for the 23,280 genes examined. These 23,280 
genes were selected on the base of the presence of 2 and more variants per gene and unique mapping 
coordinates. We further examined top genes and excluded those that were driven by single variant with 
the differences in clustering between versions of genotyping platforms in our analysis. This included 
monomorphic rs1058065 (EIF2B4) .
Further, we investigated variants contributing to the gene-based test. To determine whether genes 
identified in SKAT-O were enriched for particular molecular pathways, we performed a gene ontology 
(GO) enrichment analysis on a sorted by p value list of genes , using Gene Ontology enRIchment anaL-
ysis and visuaLizAtion tool (GOrilla)60,61.
Search for candidate high-penetrance CRC alleles. We considered the possibility that rare dam-
aging variants represented on the exome array might confer high-penetrance susceptibility to CRC and 
conducted exploratory data analysis. We reasoned on the basis of pre-existing empiric data that any 
dominant alleles would be likely to have frequencies of < 0.1%, whereas recessive alleles would have 
frequencies of < 2% in controls. Dominant alleles were filtered from the entire variant set as follows: [1] 
predicted not to be benign/tolerated by both SIFT18 and PolyPhen217 or nonsense variants; [2] excluded 
probable miscalled SNPs through visual inspection of genotyping clusters; [3] absent in controls to 
ensure inclusion of potentially high penetrance risk alleles. Recessive alleles were filtered from the entire 
variant set as follows: [1] predicted not benign or tolerated by both SIFT18 and PolyPhen217; [2] excluded 
probable miscalled SNPs through visual inspection of genotyping; [3] homozygotes absent in controls to 
ensure inclusion of potentially high penetrance risk alleles; [4] minor allele frequency ≤ 0.02 in controls.
We evaluated effect of rare damaging variants under dominant or recessive model of inheritance 
using Fisher’s exact test in a pooled analysis. Due to the limited number of rare damaging variants on 
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traditional GWAS platforms, we included in the analysis case-control series genotyped using Exome 
Array only (8100 cases/21820 controls). We also looked for evidence of an excess of compound hete-
rozygosity for rare damaging variants in cases compared to controls. The compound heterozygous list 
was filtered from the entire set of heterozygous variants as follows: (1) excluded probable miscalled SNPs 
through visual inspection of genotyping clusters, [2] predicted not to be benign/tolerated by both SIFT18 
and PolyPhen217, (3) number of rare damaging heterozygotes per gene in controls ≤ 1, (4) minor allele 
frequency ≤ 2% in controls. We further look for excess of rare damaging homozygous variants in DNA 
repair pathways by counting number of homozygous rare variants in cases and controls and testing sig-
nificance by Fisher exact test. Although this study did not have power to detect such alleles by association 
testing or by gene burden tests, we catalogued all candidate alleles that fulfilled these criteria.
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